Bayer initiates Phase III Studies with Investigational Contrast Agent Gadoquatrane
Comprehensive clinical development program called QUANTI includes two Phase III studies in adults and one pediatric study investigating gadoquatrane for use in MRI across all body regions and across ages from birth to adulthood
United States Michael Forsting Konstanze Diefenbach National Institute Of Biomedical Imaging Global Head Of Radiology Research Development University Essen
Source: itnonline.com